Glatiramer Acetate Co-Polymer Antimicrobial Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial peptides, such as LL-37, pose risks to human cells due to their positive charge, leading to unwanted effects and potential microbial resistance, while increasing antimicrobial resistance threatens effective treatment of microbial infections.
Innovation Solution
A positively charged co-polymer composed of at least 75 molar percent amino acids from alanine, lysine, glutamate, arginine, and tyrosine or their derivatives, specifically glatiramer acetate, is developed for use as an antimicrobial agent, which can be used to treat or prevent microbial infections, including bacterial infections like Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antimicrobial peptides with positive charge are used to eradicate microbial organisms, then antimicrobial efficacy is improved, but harmful effects on human cells increase
Solution Approach 1:
The patent applies local quality by designing a copolymer with non-uniform charge distribution through specific amino acid sequencing. The polymer contains clusters of positively charged residues (lysine, arginine) separated by negatively charged residues (glutamate, aspartate), creating localized positive charge regions that selectively interact with microbial membranes while minimizing interaction with human cells. This local charge concentration strategy enhances antimicrobial efficacy at specific interaction sites without proportionally increasing harm to human cells.
Solution Approach 2:
The patent employs parameter changes by systematically varying the composition ratios of amino acids (lysine: 20-40%, arginine: 10-30%, glutamate: 20-40%, aspartate: 10-30%) and controlling the degree of polymerization (5-50 residues). These parameter adjustments optimize the balance between positive charge density (for antimicrobial activity) and overall polymer properties (for reduced cytotoxicity). The specific parameter range achieves maximum microbial membrane disruption while maintaining safety for human cells.
2Reliability
If conventional antibiotics are used to treat microbial infections, then treatment effectiveness is maintained, but antimicrobial resistance develops
Solution Approach 1:
The patent applies copying by mimicking the structure and mechanism of natural host defense peptides (such as LL-37, defensins, and cathelicidins) that have evolved to combat infections without inducing resistance. The copolymer replicates key features of these endogenous peptides: amphipathic structure, cationic charge, and membrane-disrupting mechanism. By copying nature's time-tested solution, the invention achieves antimicrobial effectiveness while avoiding the resistance problems associated with conventional antibiotics.
Solution Approach 2:
The patent converts the typically harmful effect of membrane disruption into a beneficial antimicrobial mechanism. While membrane disruption can be toxic to both microbial and human cells, the patent exploits the difference in membrane composition between microbes and human cells. The copolymer selectively targets microbial membranes due to their higher negative charge density and different lipid composition, converting what would normally be a non-specific toxic effect into a selective antimicrobial action that does not promote resistance.
3Reliability
If copolymer composition is optimized for antimicrobial activity, then efficacy against microbes is improved, but selectivity against human cells may be reduced
Solution Approach 1:
The patent applies segmentation by dividing the copolymer into distinct functional segments or blocks with different amino acid compositions. The polymer contains alternating segments of positively charged amino acids (lysine-rich and arginine-rich regions) and negatively charged amino acids (glutamate-rich and aspartate-rich regions). This segmented architecture creates localized interaction zones that selectively bind to microbial membranes while the overall polymer structure maintains selectivity through the balanced charge distribution. Each segment contributes differently to microbial binding and membrane disruption, enabling high antimicrobial activity with preserved selectivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The glatiramer acetate co-polymer effectively kills or inhibits microbial growth with a high minimal inhibitory concentration against gram-negative bacteria like E. coli and P. aeruginosa, while showing lower efficacy against gram-positive bacteria like S. aureus, and retains activity in human serum and high salt concentrations, offering a safer alternative to traditional antimicrobial peptides.
Implementation Method 1
The electrostatic interactions allow these peptides to permeabilize the membrane lipid bilayer, thereby leading to the formation of membrane pores, cell depolarization, leakage of intracellular contents, and ultimately cell death
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2A~2B
AI summary
The present invention provides a positively charged co-polymer for use as an antimicrobial agent,wherein said positively charged co-polymer is composed of amino acids and/or derivatives thereof and wherein at least 75 molar percent of said amino acids are selected from the group consisting of alanine, lysine, glutamate, arginine and tyrosine and/or derivatives thereof. The present invention also provides methods for treating, preventing or ameliorating a microbial infection comprising administration of positively charged random co-polymers as well as a pharmaceutical composition comprising said co-polymer. The invention further provides a kit of parts comprising the positively charged random co-polymer.